Compare Amgen, Inc. (AMGN) vs Chart Industries Inc (GTLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Chart Industries Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Chart Industries Inc trades at $209.79 (market cap $10.05B). The key difference: Amgen, Inc. is far larger — about 19.5× Chart Industries Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| AMGN | GTLS | |
|---|---|---|
Market Cap | $196.12B | $10.05B |
Sector | Health | Technology |
52-Week High | $388.16 | $209.87 |
52-Week Low | $271.18 | $164.90 |
Enterprise Value | $241.41B | $13.57B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GTLS trades at $209.87, up 0.13% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported $4.26B revenue in 2025 but missed EPS estimates for three consecutive quarters, with negative net income margin and ROE. Recent news highlights Baker Hughes' pending $13.6B acquisition, which secured EU antitrust approval in July 2026, providing a significant catalyst.
The stock's outlook is supported by strong analyst buy ratings (54%) and the acquisition premium, but risks include consistent earnings misses, profitability challenges, and integration execution. Valuation appears stretched with a P/E of 629.67, suggesting cautious optimism hinges on deal completion and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
